Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Top Cited Papers
Open Access
- 8 December 2011
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 365 (23), 2155-2166
- https://doi.org/10.1056/nejmoa1104875
Abstract
Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion.Keywords
This publication has 27 references indexed in Scilit:
- New Regimens to Prevent Tuberculosis in Adults with HIV InfectionNew England Journal of Medicine, 2011
- Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Update on Rifampin and Rifabutin Drug InteractionsThe American Journal of the Medical Sciences, 2008
- Pharmacokinetics of Rifapentine in ChildrenThe Pediatric Infectious Disease Journal, 2006
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2006
- Priorities for the Treatment of Latent Tuberculosis Infection in the United StatesNew England Journal of Medicine, 2004
- A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug usersAmerican Journal Of Medicine, 2001
- Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin AntibacterialsClinical Pharmacokinetics, 2001
- Twice weekly tuberculosis preventive therapy in HIV infection in ZambiaAIDS, 1998
- Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemicPublished by American Medical Association (AMA) ,1995